ALKS (Alkermes) Insider Ownership: 2.31 % (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALKS Alkermes PLC ALKS
64 GF Score
Price $48.34
GF Value $32.15
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alkermes Insider Ownership?

Alkermes ALKS +0.62% 64 Insider Ownership is 2.31 % as of Aug. 23, 2026. GuruFocus rates ALKS with a GF Score™ of 64/100 and a GF Value™ of $32.15 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alkermes's insider ownership is 2.31%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alkermes's Institutional Ownership is 105.59%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alkermes's Float Percentage Of Total Shares Outstanding is 72.17%.

Alkermes Insider Ownership Historical Data

* Premium members only.

The historical data trend for Alkermes's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes Insider Ownership Chart

Alkermes Historical Data

The historical data trend for Alkermes can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 2.23 2.23 2.23 2.22 2.22 2.22 2.33 2.34 2.33 2.31
ALKS
64GF Score
Alkermes PLC ALKS
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alkermes Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 2.31 % mean?
Alkermes (ALKS) has a Insider Ownership of 2.31 % as of Aug. 23, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Alkermes and its competitors.
Is Alkermes' Insider Ownership too high?
Alkermes' current Insider Ownership is 2.31 %. Overall, Alkermes has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' Insider Ownership compare to LQDA and LNTH?
Alkermes' Insider Ownership of 2.31 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Alkermes and its competitors. Alkermes's current Insider Ownership is 2.31 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (ALKS) is currently considered Significantly Overvalued. The stock's GF Value™ is $32.15, compared to a current price of $48.34 — trading 50.4% above its estimated fair value. The current Insider Ownership is 2.31 %. Alkermes' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Alkermes (ALKS), the current Insider Ownership is 2.31 % as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkermes (ALKS) Overvalued in 2026?

Based on GuruFocus' analysis, Alkermes stock appears to be overvalued. The current stock price of $48.34 is trading 50.4% above its estimated GF Value™ of $32.15. GuruFocus considers Alkermes to be Significantly Overvalued.

Key valuation signals for ALKS:

  • Insider Ownership: 2.31 %
  • GF Value™: $32.15 vs. price of $48.34 (50.4% above fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the ALKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alkermes Business Description

Other Exchanges 8AK:Germany
Address 1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
64GF Score

Get the complete analysis for ALKS

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$48.34
Price
$32.15
GF Value